カテゴリ： 世界, 医療/バイオ, Market Monitor Global

CAR T細胞ベース薬剤のグローバル市場展望 2023年-2029年：CD19標的、BCMA標的

■ 英語タイトル：Drug based on CAR T-Cell Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8481）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8481
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：106
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[CAR T細胞ベース薬剤のグローバル市場展望 2023年-2029年：CD19標的、BCMA標的]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のCAR T細胞ベース薬剤市場規模と予測を収録しています。・世界のCAR T細胞ベース薬剤市場：売上、2018年-2023年、2024年-2029年
・世界のCAR T細胞ベース薬剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のCAR T細胞ベース薬剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「CD19標的」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

CAR T細胞ベース薬剤のグローバル主要企業は、Novartis、 Gilead Sciences、 Bristol-Myers Squibb、 J & J、 JW Therapeutics、 FOSUNKite、 CARsgen Therapeutics (Pipeline)、 CARsgen Therapeutics、 Autolus Therapeutics、 Sorrento Therapeutics、 Mustang Bio、 Bluebird Bio、 Cellectis、 Allogene Therapeutics、 Celyadなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、CAR T細胞ベース薬剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のCAR T細胞ベース薬剤市場：タイプ別、2018年-2023年、2024年-2029年
世界のCAR T細胞ベース薬剤市場：タイプ別市場シェア、2022年
・CD19標的、BCMA標的

世界のCAR T細胞ベース薬剤市場：用途別、2018年-2023年、2024年-2029年
世界のCAR T細胞ベース薬剤市場：用途別市場シェア、2022年
・リンパ腫、多発性骨髄腫

世界のCAR T細胞ベース薬剤市場：地域・国別、2018年-2023年、2024年-2029年
世界のCAR T細胞ベース薬剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるCAR T細胞ベース薬剤のグローバル売上、2018年-2023年
・主要企業におけるCAR T細胞ベース薬剤のグローバル売上シェア、2022年
・主要企業におけるCAR T細胞ベース薬剤のグローバル販売量、2018年-2023年
・主要企業におけるCAR T細胞ベース薬剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Novartis、 Gilead Sciences、 Bristol-Myers Squibb、 J & J、 JW Therapeutics、 FOSUNKite、 CARsgen Therapeutics (Pipeline)、 CARsgen Therapeutics、 Autolus Therapeutics、 Sorrento Therapeutics、 Mustang Bio、 Bluebird Bio、 Cellectis、 Allogene Therapeutics、 Celyad

*************************************************************

・調査・分析レポートの概要
CAR T細胞ベース薬剤市場の定義
市場セグメント
世界のCAR T細胞ベース薬剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のCAR T細胞ベース薬剤市場規模
世界のCAR T細胞ベース薬剤市場規模：2022年 VS 2029年
世界のCAR T細胞ベース薬剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのCAR T細胞ベース薬剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のCAR T細胞ベース薬剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：CD19標的、BCMA標的
CAR T細胞ベース薬剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：リンパ腫、多発性骨髄腫
CAR T細胞ベース薬剤の用途別グローバル売上・予測

・地域別市場分析
地域別CAR T細胞ベース薬剤市場規模 2022年と2029年
地域別CAR T細胞ベース薬剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Novartis、 Gilead Sciences、 Bristol-Myers Squibb、 J & J、 JW Therapeutics、 FOSUNKite、 CARsgen Therapeutics (Pipeline)、 CARsgen Therapeutics、 Autolus Therapeutics、 Sorrento Therapeutics、 Mustang Bio、 Bluebird Bio、 Cellectis、 Allogene Therapeutics、 Celyad
...

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
This report aims to provide a comprehensive presentation of the global market for Drug based on CAR T-Cell, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug based on CAR T-Cell. This report contains market size and forecasts of Drug based on CAR T-Cell in global, including the following market information:
Global Drug based on CAR T-Cell Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Drug based on CAR T-Cell market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
CD19-targeted Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drug based on CAR T-Cell include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drug based on CAR T-Cell companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drug based on CAR T-Cell Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Drug based on CAR T-Cell Market Segment Percentages, by Type, 2022 (%)
CD19-targeted
BCMA-targeted
Global Drug based on CAR T-Cell Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Drug based on CAR T-Cell Market Segment Percentages, by Application, 2022 (%)
Lymphoma
Multiple Myeloma
Global Drug based on CAR T-Cell Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Drug based on CAR T-Cell Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug based on CAR T-Cell revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Drug based on CAR T-Cell revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drug based on CAR T-Cell, market overview.
Chapter 2: Global Drug based on CAR T-Cell market size in revenue.
Chapter 3: Detailed analysis of Drug based on CAR T-Cell company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drug based on CAR T-Cell in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Drug based on CAR T-Cell Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drug based on CAR T-Cell Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drug based on CAR T-Cell Overall Market Size
2.1 Global Drug based on CAR T-Cell Market Size: 2022 VS 2029
2.2 Global Drug based on CAR T-Cell Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drug based on CAR T-Cell Players in Global Market
3.2 Top Global Drug based on CAR T-Cell Companies Ranked by Revenue
3.3 Global Drug based on CAR T-Cell Revenue by Companies
3.4 Top 3 and Top 5 Drug based on CAR T-Cell Companies in Global Market, by Revenue in 2022
3.5 Global Companies Drug based on CAR T-Cell Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drug based on CAR T-Cell Players in Global Market
3.6.1 List of Global Tier 1 Drug based on CAR T-Cell Companies
3.6.2 List of Global Tier 2 and Tier 3 Drug based on CAR T-Cell Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Drug based on CAR T-Cell Market Size Markets, 2022 & 2029
4.1.2 CD19-targeted
4.1.3 BCMA-targeted
4.2 By Type – Global Drug based on CAR T-Cell Revenue & Forecasts
4.2.1 By Type – Global Drug based on CAR T-Cell Revenue, 2018-2023
4.2.2 By Type – Global Drug based on CAR T-Cell Revenue, 2024-2029
4.2.3 By Type – Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drug based on CAR T-Cell Market Size, 2022 & 2029
5.1.2 Lymphoma
5.1.3 Multiple Myeloma
5.2 By Application – Global Drug based on CAR T-Cell Revenue & Forecasts
5.2.1 By Application – Global Drug based on CAR T-Cell Revenue, 2018-2023
5.2.2 By Application – Global Drug based on CAR T-Cell Revenue, 2024-2029
5.2.3 By Application – Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Drug based on CAR T-Cell Market Size, 2022 & 2029
6.2 By Region – Global Drug based on CAR T-Cell Revenue & Forecasts
6.2.1 By Region – Global Drug based on CAR T-Cell Revenue, 2018-2023
6.2.2 By Region – Global Drug based on CAR T-Cell Revenue, 2024-2029
6.2.3 By Region – Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Drug based on CAR T-Cell Revenue, 2018-2029
6.3.2 US Drug based on CAR T-Cell Market Size, 2018-2029
6.3.3 Canada Drug based on CAR T-Cell Market Size, 2018-2029
6.3.4 Mexico Drug based on CAR T-Cell Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Drug based on CAR T-Cell Revenue, 2018-2029
6.4.2 Germany Drug based on CAR T-Cell Market Size, 2018-2029
6.4.3 France Drug based on CAR T-Cell Market Size, 2018-2029
6.4.4 U.K. Drug based on CAR T-Cell Market Size, 2018-2029
6.4.5 Italy Drug based on CAR T-Cell Market Size, 2018-2029
6.4.6 Russia Drug based on CAR T-Cell Market Size, 2018-2029
6.4.7 Nordic Countries Drug based on CAR T-Cell Market Size, 2018-2029
6.4.8 Benelux Drug based on CAR T-Cell Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Drug based on CAR T-Cell Revenue, 2018-2029
6.5.2 China Drug based on CAR T-Cell Market Size, 2018-2029
6.5.3 Japan Drug based on CAR T-Cell Market Size, 2018-2029
6.5.4 South Korea Drug based on CAR T-Cell Market Size, 2018-2029
6.5.5 Southeast Asia Drug based on CAR T-Cell Market Size, 2018-2029
6.5.6 India Drug based on CAR T-Cell Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Drug based on CAR T-Cell Revenue, 2018-2029
6.6.2 Brazil Drug based on CAR T-Cell Market Size, 2018-2029
6.6.3 Argentina Drug based on CAR T-Cell Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Drug based on CAR T-Cell Revenue, 2018-2029
6.7.2 Turkey Drug based on CAR T-Cell Market Size, 2018-2029
6.7.3 Israel Drug based on CAR T-Cell Market Size, 2018-2029
6.7.4 Saudi Arabia Drug based on CAR T-Cell Market Size, 2018-2029
6.7.5 UAE Drug based on CAR T-Cell Market Size, 2018-2029
7 Drug based on CAR T-Cell Companies Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Drug based on CAR T-Cell Major Product Offerings
7.1.4 Novartis Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.1.5 Novartis Key News & Latest Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Summary
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Drug based on CAR T-Cell Major Product Offerings
7.2.4 Gilead Sciences Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.2.5 Gilead Sciences Key News & Latest Developments
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Company Summary
7.3.2 Bristol-Myers Squibb Business Overview
7.3.3 Bristol-Myers Squibb Drug based on CAR T-Cell Major Product Offerings
7.3.4 Bristol-Myers Squibb Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.3.5 Bristol-Myers Squibb Key News & Latest Developments
7.4 J & J
7.4.1 J & J Company Summary
7.4.2 J & J Business Overview
7.4.3 J & J Drug based on CAR T-Cell Major Product Offerings
7.4.4 J & J Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.4.5 J & J Key News & Latest Developments
7.5 JW Therapeutics
7.5.1 JW Therapeutics Company Summary
7.5.2 JW Therapeutics Business Overview
7.5.3 JW Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.5.4 JW Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.5.5 JW Therapeutics Key News & Latest Developments
7.6 FOSUNKite
7.6.1 FOSUNKite Company Summary
7.6.2 FOSUNKite Business Overview
7.6.3 FOSUNKite Drug based on CAR T-Cell Major Product Offerings
7.6.4 FOSUNKite Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.6.5 FOSUNKite Key News & Latest Developments
7.7 CARsgen Therapeutics (Pipeline)
7.7.1 CARsgen Therapeutics (Pipeline) Company Summary
7.7.2 CARsgen Therapeutics (Pipeline) Business Overview
7.7.3 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Major Product Offerings
7.7.4 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.7.5 CARsgen Therapeutics (Pipeline) Key News & Latest Developments
7.8 CARsgen Therapeutics
7.8.1 CARsgen Therapeutics Company Summary
7.8.2 CARsgen Therapeutics Business Overview
7.8.3 CARsgen Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.8.4 CARsgen Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.8.5 CARsgen Therapeutics Key News & Latest Developments
7.9 Autolus Therapeutics
7.9.1 Autolus Therapeutics Company Summary
7.9.2 Autolus Therapeutics Business Overview
7.9.3 Autolus Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.9.4 Autolus Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.9.5 Autolus Therapeutics Key News & Latest Developments
7.10 Sorrento Therapeutics
7.10.1 Sorrento Therapeutics Company Summary
7.10.2 Sorrento Therapeutics Business Overview
7.10.3 Sorrento Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.10.4 Sorrento Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.10.5 Sorrento Therapeutics Key News & Latest Developments
7.11 Mustang Bio
7.11.1 Mustang Bio Company Summary
7.11.2 Mustang Bio Business Overview
7.11.3 Mustang Bio Drug based on CAR T-Cell Major Product Offerings
7.11.4 Mustang Bio Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.11.5 Mustang Bio Key News & Latest Developments
7.12 Bluebird Bio
7.12.1 Bluebird Bio Company Summary
7.12.2 Bluebird Bio Business Overview
7.12.3 Bluebird Bio Drug based on CAR T-Cell Major Product Offerings
7.12.4 Bluebird Bio Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.12.5 Bluebird Bio Key News & Latest Developments
7.13 Cellectis
7.13.1 Cellectis Company Summary
7.13.2 Cellectis Business Overview
7.13.3 Cellectis Drug based on CAR T-Cell Major Product Offerings
7.13.4 Cellectis Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.13.5 Cellectis Key News & Latest Developments
7.14 Allogene Therapeutics
7.14.1 Allogene Therapeutics Company Summary
7.14.2 Allogene Therapeutics Business Overview
7.14.3 Allogene Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.14.4 Allogene Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.14.5 Allogene Therapeutics Key News & Latest Developments
7.15 Celyad
7.15.1 Celyad Company Summary
7.15.2 Celyad Business Overview
7.15.3 Celyad Drug based on CAR T-Cell Major Product Offerings
7.15.4 Celyad Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.15.5 Celyad Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • CAR-T細胞治療薬のグローバル市場展望 2023年-2029年：CD19標的、BCMA標的
  • 万能細胞治療薬のグローバル市場展望 2023年-2029年：細胞治療、遺伝子治療、幹細胞治療
  • 同種幹細胞移植のグローバル市場展望 2023年-2029年：非改変幹細胞移植、T細胞除去移植、臍帯血移植、ドナーリンパ球注入
  • ライブセル3Dカプセル化のグローバル市場展望 2023年-2029年：アルギン酸、キトサン、セルロース、その他
  • 創傷治癒用幹細胞治療のグローバル市場展望 2023年-2029年：間葉系幹細胞、脂肪由来幹細胞、骨髄由来幹細胞、胚性幹細胞、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8481 )"CAR T細胞ベース薬剤のグローバル市場展望 2023年-2029年：CD19標的、BCMA標的" (英文：Drug based on CAR T-Cell Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。